维莫德吉治疗晚期基底细胞癌的疗效与安全性分析:真实世界多中心队列研究
这项回顾性多中心队列研究分析了2017年8月1日至2020年12月31日期间接受维莫德吉治疗的108例局部晚期或转移性基底细胞癌患者,中位无进展生存期为30.5个月(95%CI 24.8-36.3),中位总生存期为41.5个月(95%CI 31.6-51.3),女性是无进展生存的独立阳性预后因素,治疗耐受性良好。
要点
- 维莫德吉治疗晚期基底细胞癌中位无进展生存期30.5个月,中位总生存期41.5个月。
- 女性是无进展生存的独立阳性预后因素。
- 治疗耐受性良好,安全性特征与既往研究基本一致。
核心结论
- 治疗反应是反应维持和更好总生存的预后因素。
- 维莫德吉治疗耐受性良好,安全性特征与既往研究基本一致。
研究设计与样本
- 回顾性多中心队列研究,纳入国家药物项目治疗的108例局部晚期或转移性基底细胞癌患者,治疗时间为2017年8月1日至2020年12月31日。
- 疗效评估依据CT/MRI扫描和实体瘤疗效评价标准(RECIST)1.1,安全性评估依据常见不良事件术语标准v.5.0(CTCAE)。
主要发现
- 中位治疗时间为14个月(范围1-94个月)。
- 中位无进展生存期为30.5个月(95%CI 24.8-36.3),6、12和24个月无进展生存率分别为92%、78%和61%。
- 中位总生存期为41.5个月(95%CI 31.6-51.3),1、2和3年总生存率分别为86%、73%和60%。
- 单变量和多变量分析表明女性是无进展生存的独立阳性预后因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Basal cell carcinoma (BCC) is the most frequent non-melanoma skin cancer. The basis of treatment is surgical resection. The treatment of locally advanced and metastatic disease is currently based on sonidegb or vismodegib, small molecule inhibitors of the hedgehog signalling pathway. OBJECTIVES: The study aimed to retrospectively analyse the efficacy and safety of treatment with vismodegib in 108 patients with locally advanced or metastatic disease treated from August 1st, 2017 to December 31st, 2020. The primary objective was to evaluate the objective response rate (ORR), overall survival (OS) and progression-free survival rates. The secondary aims of the study were the disease control rate, the incidence of adverse events (AEs) and the estimation of the factors that potentially impact the treatment outcome and patient survival. METHODS: Patients treated in national drug programme were enrolled into this retrospective cohort study. Evaluation of the treatment efficacy was performed according to CT/MRI scans and by the response evaluation criteria in solid tumours (RECIST) 1.1. The safety evaluation was performed according to the Common Terminology Criteria for Adverse Events v. 5.0 (CTCAE) classification and severity assessment. RESULTS: The median duration of treatment was 14 months (range 1-94 months). The median progression-free survival reached 30.5 months (95% CI; 24.8-36.3), and the progression-free survival rate after 6, 12 and 24-months were 92%, 78% and 61%, respectively. The median overall survival was 41.5 months (95% CI; 31.6-51.3), and the overall survival rate after 1, 2 and 3 years accordingly 86%, 73% and 60%. The univariant and multivariant analysis indicated that the female gender is an independent positive prognostic factor of progression-free survival. CONCLUSIONS: The response to treatment is the prognostic factor for response maintenance and better overall survival. The therapy was well tolerated with the safety profile consistent in general with known from previous studies.
引用
- Słowińska M, Dudzisz-Śledź M, Sobczuk P, et al. Analysis of efficacy and safety of vismodegib therapy in patients with advanced basal cell carcinoma - real world multicenter cohort study. J Eur Acad Dermatol Venereol. 2022. PMID: 35279879. doi:10.1111/jdv.18070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。